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Anticholinergic medications are widely used in older adults and are a common 
source of adverse events in this population. Common drug classes include antiar-
rhythmics, antidepressants, antiemetics, first generation antihistamines, urinary 
incontinence antimuscarinic agents, antiparkinsonian agents, antipsychotics, 
antispasmodics, and skeletal muscle relaxants. These drugs have been associated 
with delirium, cognitive impairment, sedation, dizziness, falls, fracture, constipa-
tion, urinary retention, blurred vision, tachycardia and dry mouth. If possible, 
these drugs should be avoided in older adults or less toxic agents within the class 
should be utilized. This chapter will explore the mechanism of action of anticho-
linergic drugs at both the cellular and organ system level; discuss how to assess 
for anticholinergic drug burden; list medications with anticholinergic effects as 
identified in the Beer’s criteria on potentially inappropriate medication use in older 
adults; review anticholinergic drug–drug interactions; describe contraindications 
to the use of anticholinergic agents; and explore practical considerations such as the 
availability of these substances in nonprescription medications, their use at end of 
life and deprescribing.
Keywords: anticholinergic medications, Beer’s criteria, adverse drug events, 
older adults, geriatrics
1. Introduction
1.1 Anticholinergic agents in nature
Anticholinergic agents are substances that antagonize the effects of acetylcholine, 
a neurotransmitter formed by an ester of choline and acetic acid, that facilitates nerve 
impulses in both the central (CNS) and peripheral nervous systems. Acetylcholine 
is the main neurotransmitter of the parasympathetic system. It is also located within 
parts of the autonomic nervous system [1]. Anticholinergic agents are present in both 
pharmaceuticals and in nature. Substances like hyoscyamine and belladonna are nat-
urally occurring anticholinergics which have been used medicinally to control gastric 
secretions, for irritable bowel symptoms, and for urinary spasms [2]. However, 
despite their natural origins, the use of these drugs is not without  consequence and 
should be avoided in older adults.
Update in Geriatrics
2
2. Anticholinergics physiological effects
2.1 Mechanisms of action
The cholinergic receptors are divided into muscarinic receptors or nicotinic 
receptors. There are five subtypes of muscarinic receptors, M1-M5 and two types 
of nicotinic receptors, NM (skeletal muscle) and NN (neuronal). M1 are found 
in the CNS (i.e., the cerebral cortex, hippocampus, striatum and thalamus), 
autonomic ganglia, gastric and salivary glands and the enteric nerves of the GI 
tract. M2 are located in the CNS (i.e., the hindbrain, thalamus, cerebral cortex, 
hippocampus, striatum, heart, smooth muscle, and autonomic nerve terminals). 
M3 receptors have less of a presence in the CNS although they are found in the 
cerebral cortex and hippocampus. They are abundant in smooth muscle and 
glands and the heart. M4 is preferentially expressed in the CNS (i.e., forebrain, 
striatum, cerebral cortex and hippocampus) while M5 are only expressed in low 
levels in the CNS and periphery and are found primarily in the substantia nigra 
and ventral tegmentum area. NM are located at the neuromuscular junction and 
are involved in muscle contraction. Nn are found in the autonomic ganglia and 
adrenal medulla [3].
At the cellular level, anticholinergic agents act by opposing the effects of acetyl-
choline either at the muscarinic or nicotinic receptors. In the geriatric population, 
most anticholinergic drugs affect the muscarinic receptors. On the organ system 
level, these compounds have varying effects. Although some effects are therapeutic, 
it’s their toxic effects that are most worrisome, especially in geriatric patients.
While M1-M5 receptors are found in the brain, most of the deleterious effects 
on the CNS come from antagonizing M1 receptors. This can lead to delirium, 
cognitive impairment, dizziness, sedation and confusion. The predominant form 
of muscarinic receptors in the eyes are M3 although M1-M5 receptors are also 
present. Blocking these receptors leads to mydriasis and blurred vision. It is for 
this reason that ophthalmic atropine, a potent anticholinergic agent, is used to 
produce pupillary dilation and/or cycloplegia. Blocking of M1 and M3 receptors 
in salivary glands leads to dry mouth and difficulty swallowing whereas oppos-
ing the effects of M3 receptors in sweat glands leads to the inability to dissipate 
heat and can result in overheating, especially during the warmer months. The 
heart is primarily composed of M2 receptors and antagonizing these receptors 
leads to sinus tachycardia and increased contractility. Systemic atropine is used 
in the management of symptomatic sinus bradycardia and atrioventricular nodal 
block. The lungs primarily contain M1-M4 receptors and blocking these recep-
tors results in bronchodilation. The use of long- and short-acting inhalation 
antimuscarinic agents in chronic obstructive pulmonary disease (COPD) takes 
advantage of this beneficial effect. Opposing M2 and M3 receptors in the GI tract 
can lead to gastric stasis and constipation. On the other hand, dicyclomine is an 
anticholinergic drug that is used for abdominal pain associated with irritable 
bowel syndrome. Antagonism of M3 receptors in the bladder inhibits detrusor 
and bladder contractions and is used therapeutically for urinary incontinence. 
This blockade can also lead to urinary retention. The role of cholinergic agents 
in the skin, which contains primarily M3 receptors, is complex resulting in 
increased nitric oxide production and vasodilation and it also involves interplay 
with nicotinic receptors [4].
Nicotinic agents act either as neuromuscular blockers (i.e., atracurium, 
vecuronium, tubocurarine, pancuronium) or ganglionic blockers (i.e., mecamyla-
mine). Succinylcholine is a NM receptor agonist [4].
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3. Assessment of anticholinergic burden
The effects of anticholinergic agents are cumulative and there are various tools 
available to help evaluate the degree of ‘cholinergic burden’ in an older adult’s 
drug regimen. Early work by Tune et al. resulted in the development of the serum 
anticholinergic assay, a biologic measure intended to quantify anticholinergic drug 
burden [5]. Using this assay, it has been shown that many drugs taken by older 
adults have high serum anticholinergic activity Table 1 [6].
Over 600 medications have some degree of anticholinergic activity [7]. One 
drawback of using the serum anticholinergic assay is that it may not be readily avail-
able in clinical settings and even if available, there can be a delay in care pending 
interpretation of results [8].
As a result of these limitations, scales have been developed to easily calculate 
the cumulative anticholinergic burden. The Anticholinergic Cognitive Burden Scale 
(ACBS) rates drugs on a scale of 0 (no anticholinergic effect) to 3 with 1 repre-
senting a possible anticholinergic effect based on laboratory tests but no evidence 
of clinically relevant cognitive effects and scores of 2 or 3 indicating definite 
anticholinergic effects. Higher scores indicate greater anticholinergic burden and 
warrant a re-evaluation of the drug regimen. The presence of a drug scoring 2 or 
3 can increase the risk of cognitive impairment by 46% over 6 years. Further, each 
point increase in the ACBS has been associated with a decrease in the Mini-Mental 
Examination Score of 0.33 points over the course of 2 years. This point increase has 
also been associated with a 26% increase in the risk of death [9].
Another tool is the Anticholinergic Risk Scale (ARS). Similar to ACBS, the ARS 
is also a 3-point scale. The developers of the scale assessed whether the ARS could 
predict the risk of anticholinergic adverse effects in a geriatric evaluation and man-
agement (GEM) group and in a primary care (PC) group. The investigators found 
that in the GEM group, older adults experienced more adverse CNS effects whereas 
in the PC group, more elderly had peripheral adverse effects [10].
The Anticholinergic Drug Scale (ADS), which was previously known as the 
Clinician-Rated Anticholinergic Scale, is another 3-point scale. It includes the 
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largest number of anticholinergic agents. A score of 0 indicates no known anti-
cholinergic properties; a score of 1 means that the drug has the potential for anti-
cholinergic activity as evidenced by receptor binding sites; a score of 2 represents 
a drug that causes anticholinergic adverse effects at higher doses; and a score of 3 
represents a drug with marked anticholinergic activity [11].
The Anticholinergic Burden Classification (ABC) measures serum anticholin-
ergic activity but takes into account the duration of exposure, adjusts for mode 
of administration (i.e., topical, nasal, oral, etc.), assesses for possible drug–drug 
interactions and for the ability of drugs to cross the blood brain barrier [12].
The Anticholinergic Activity Scale (AAS) is based on in vivo radioreceptor assay 
determinations and ranks drugs on five levels: 0 (no anticholinergic activity); 
0/+ (no or minimal anticholinergic activity); + (low anticholinergic activity), ++ 
(moderate anticholinergic activity), and +++ (high anticholinergic activity) [13].
The Anticholinergic Loading Scale (ALS) is a tool used in the Australian 
Imaging, Biomarkers and Lifestyle (AIBL) study that calculates anticholinergic 
load. Anticholinergic load was found to have an adverse effect on psychomotor 
speed and executive function in healthy controls [14].
The Anticholinergic Effect on Cognition Scale (AECS) is another 3-point scale 
that uses in vitro anticholinergic potency as well as a drug’s ability to cross the blood 
brain barrier [15].
Unlike the previous scales, which only focus on the anticholinergic potential of 
a drug regimen, the Drug Burden Index (DBI) takes into account anticholinergic 
effects, sedative effects of medications, and the total number of medications. It 
measures the effect of cumulative exposure to both anticholinergic and sedative 
medications on physical and cognitive function in older adults. This scale is based 
on the minimum recommended daily doses of each drug. Drugs that have both anti-
cholinergic and sedative properties are classified based on their anticholinergic 
effects [16]. The developers studied this scale in over 3000 healthy community-
dwelling older adults aged 70–79 years. They found that the use of anticholinergic 
and sedative medications was associated with poorer physical performance and 
cognitive performance. Each unit of drug burden on physical function was equal to 
having three additional physical comorbidities whereas each unit of drug burden on 
cognition was similar to having four additional physical comorbidities or about half 
of the effects of anxiety, depression or cognitive impairment [17].
A recent publication compared several of the anticholinergic scales providing a 
description of the tool and listing the number of drugs with anticholinergic activ-
ity that are included in the scale [18]. However, while many of these scales have 
shown a significant correlation between anticholinergic burden assessment and 
serum anticholinergic drug levels, they have limitations. There is currently no ‘gold 
standard’ to identify an anticholinergic drug. Only parent compounds are included in 
these scales, therefore, there is no information on active metabolites that may also 
contribute to the anticholinergic burden. While some scales do take dose into the 
account, this is not consistently done in all tools. These scales also assume that there 
is a linear relationship between anticholinergic levels and toxicity. Lastly, serum 
anticholinergic activity assays do not distinguish between agonist versus antagonist 
binding of the cholinergic receptors [19].
4.  Medication classes with anticholinergic effects- the Beer’s list of 
potentially inappropriate medications in older adults
In 1991, Dr. Mark Beers published explicit criteria for the use of ‘potentially 
inappropriate medications’ or PIMS in older nursing home residents [20]. The 
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Beer’s criteria, which were developed using a two-stage Delphi survey, defined 
inappropriate prescribing as the use of a medication where the potential risks 
outweigh the potential benefits. These initial criteria included 30 therapeutic 
classes/medications that should be avoided in elderly nursing home residents [21]. 
This list is updated every 3 years by the American Geriatrics Society. At the time of 
this writing, the latest Beer’s List was published in 2019. The criteria identifies PIMs, 
drugs that may be PIMS because they may exacerbate disease states or geriatric 
syndromes, drugs that should be used with caution, drugs that should be avoided, 
drugs that should be used in reduced doses (if at all) based on renal function, and 
drugs with strong anticholinergic properties Table 2 [22].
5. Adverse effects of anticholinergics (“Alice in Wonderland”)
As mentioned previously, cholinergic receptors are found in various organ 
systems throughout the body. Blocking these receptors can have both therapeutic 
and toxic effects. The mnemonic “red as a beet, dry as a bone, blind as a bat, mad 
as a hatter, hot as a hare, full as a flask” reflects the classic signs and symptoms of 
anticholinergic poisoning [23]. However, adverse events in older adults may be more 
subtle. These can include drowsiness, sedation, cognitive impairment, confu-
sion, delirium, hallucinations, blurred vision, dizziness, falls/fractures, urinary 
 retention, constipation, tachycardia, and xerostomia [3, 22].
Adverse CNS effects can be particularly burdensome among older adults. A 
recent study examining the effects of PIMs in patients with dementia found that 
almost one-quarter of adults aged ≥65 with cognitive impairment used drugs 
with clinically significant anticholinergic effects. This study measured anti-
cholinergic burden using the ADS [11]. It found that the level 2 drugs that were 
most prescribed were ranitidine and cyclobenzaprine and the most commonly 
Drug Class Specific Drugs
Antiarrhythmics Disopyramide
Antidepressants Amitriptyline, amoxapine, clomipramine, desipramine, doxepin (> 6 mg), 




Brompheniramine, carbinoxamine, chlorpheniramine, clemastine, 
cyproheptadine, dexbrompheniramine, dexchlorpheniramine, dimenhydrinate, 
diphenhydramine (oral), doxylamine, hydroxyzine, meclizine, clidinium-
chlordiazepoxide, dicyclomine, homatropine (except ophthalmic), hyoscyamine, 
methscopolamine, propantheline, promethazine, pyrilamine, triprolidine
Urinary Incontinence 
Antimuscarinics





Antipsychotics Chlorpromazine, clozapine, loxapine, olanzapine, perphenazine, thioridazine, 
trifluoperazine
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prescribed level 3 drugs were meclizine, tolterodine and oxybutynin [24]. A 
systematic review examining drug-induced delirium found that ARS scores 
were consistently associated with delirium [25]. A recent retrospective analysis 
found that if older hospitalized adults scored 3 or higher on the ACBS, they 
had a 3–6 fold increased risk of developing delirium compared to those who 
score < 3 on this tool [26]. In older adults with mild to moderate Alzheimer’s 
disease who were APOE-ε4 carriers, there was a positive correlation between 
greater progression of dementia severity and continued use of anticholinergic 
 medications [27].
In addition to the CNS effects of anticholinergic agents in older adults, another 
concern is the risk of falls and fracture. After following women with a mean 
age of 55 years for approximately 24 months, the APOS (Aberdeen Prospective 
Osteoporosis Screening Study) found that those with a ACB of ≥2 had a 2.34-fold 
increased odds of having had recurrent falls in ‘later life’ with ‘later life’ referring 
to 12 months prior to follow-up; there was a 2-year follow-up period. They pos-
tulated that anticholinergic agents may contribute to falls by causing vision prob-
lems secondary to pupillary dilation, dizziness, slowed reflexes and/or cognitive 
 impairment [28].
Death, the most significant anticholinergic adverse event, was observed in a 
systematic review of studies examining the association between anticholinergic 
burden and mortality in older adults. Of the 27 studies included in this systematic 
review, 63% of studies found a positive relationship between anticholinergic drug 
burden and mortality in older adults. When solely analyzing those studies that were 
deemed to be of the highest quality, the association between anticholinergic drug use 
and death rose to 80% in the elderly [29].
6. Drug interactions involving anticholinergic agents
Besides the anticholinergic drug–drug interactions that lead to an increased 
anticholinergic burden, anticholinergic agents are involved in other potential drug–
drug interactions.
The use of an anticholinergic agent with an acetylcholinesterase inhibitor (i.e., 
donepezil, galantamine and rivastigmine) results in opposing pharmacodynamic 
effects and can negate any small, positive benefits seen with the Alzheimer’s disease 
agents [30]. Conversely, acetylcholinesterase inhibitors have the potential to 
interfere with the therapeutic effects of anticholinergic agents. Concomitant use is 
not recommended [31–33].
The concomitant administration of an anticholinergic agent and an oral solid 
dosage form of potassium supplement can increase the risk of GI bleeding. A liquid 
formulation of potassium supplement should be utilized instead if concurrent 
therapy is required [34–36].
Anticholinergic agents also interact with carbonic anhydrase inhibitors such as 
topiramate and zonisamide potentiating the risk of oligohidrosis and hyperthermia. 
Patients should be monitored for decreased sweating and increases in body tem-
perature. These combinations should be avoided [37, 38].
Concurrent use of opioids and anticholinergics can lead to severe constipa-
tion (resulting in paralytic ileus), sedation, dizziness, confusion, cognitive 
and psychomotor impairment, dry mouth and urinary retention. Caution is 
advised [39].
‘Moderate’ (i.e., drug–drug interactions for which combination therapy 
should be avoided or used only under special circumstances) anticholinergic 
drug–drug interactions include abobotulinumtoxin A, acebutolol, acetylcholine 
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ophthalmic, aclidinium, acrivastine, alfentanil, aluminum hydroxide, aman-
tadine, ambenonium, amitriptyline, amoxapine, arbutamine, aripiprazole, 
asenapine, atenolol, azatadine, belladonna, benztropine, betaxolol, bethanechol, 
biperiden, bisoprolol, brexanolone, brexpiprazole, brompheniramine, buprenor-
phine, butorphanol, calcium carbonate, carbachol ophthalmic, carbinoxamine, 
cariprazine, carteolol, carvedilol, cevimeline, chlorcyclizine, chlorphenira-
mine, chlorpromazine, cisapride, clemastine, clidinium, clomipramine, clo-
zapine, cyclizine, cyclobenzaprine, cyproheptadine, darifenacin, demecarium 
bromide ophthalmic, desipramine, dexbrompheniramine, dexchlorpheniramine, 
dezocine, dicyclomine, dimenhydrinate, diphenhydramine, disopyramide, 
doxepin, doxylamine, echothiophate iodide ophthalmic, edrophonium, elux-
adoline, ethanol, fesoterodine, flavoxate, flibanserin, fluphenazine, glycopyrro-
late, glycopyrronium topical, guanidine, haloperidol, hydroxyzine, hyoscyamine, 
iloperidone, imipramine, incobotulinumtoxin A, ipratropium, isoflurophate 
ophathalmic, kaolin, ketoconazole, labetalol, lasmiditan, levodopa, loperamide, 
loxapine, lumateperone, lurasidone, macimorelin, magaldrate, magnesium car-
bonate, magnesium hydroxide, maprotiline, meclizine, memantine, mepenzolate, 
mesoridazine, methdilazine, methotrimeprazine, methscopolamine, metoclo-
pramide, metoprolol, molindone, nadolol, nalbuphine, nebivolol, neostigmine, 
nortriptyline, olanzapine, olopatadine nasal, onabotulinumtoxin A, orphen-
adrine, oxybutynin, paliperidone, penbutolol, perphenazine, phenindamine, 
phenylephrine, physostigmine, pilocarpine, pimozide, pindolol, prabotulinum-
toxin A, pramlintide, prochlorperazine, procyclidine, promazine, prometha-
zine, propantheline, propiomazine, propranolol, protriptyline, prucalopride, 
pyridostigmine, pyrilamine, quetiapine, quinapril, remifentanil, revefenacin, 
rimabotulinumtoxin B, risperidone, scopolamine, sodium bicarbonate, solif-
enacin, sotalol, sufentanil, thiethylperazine, thioridazine, thiothixene, timolol, 
tiotropium, tizanidine, tolterodine, trifluoperazine, triflupromazine, trihexy-
phenidyl, trimeprazine, trimipramine, tripelennamine, triprolidine, trospium, 
umeclidinium and ziprasidone [40].
7. Contraindications to the use of anticholinergic agents
Anticholinergic agents cause pupillary dilation, which is detrimental in patients 
with narrow angle or primary angle closure glaucoma. When the pupils dilate, this 
increases pressure within the eye. This increase in pressure prevents drainage of 
aqueous humor from the eye resulting in marked increases in ocular pressure and 
acute pain. If left untreated, this can lead to optic nerve damage and vision loss. The 
use of anticholinergics is contraindicated in patients with this type of glaucoma [41].
In overactive bladder, there are excessive contractions of the detrusor muscle 
producing incomplete emptying of the bladder. By blocking M3 receptors in the 
genitourinary tract, this causes smooth muscle relaxation and detrusor under-
activity, which can lead to urinary retention. In the presence of benign prostate 
hyperplasia, there is compression of the urethra, which blocks the flow of urine. 
Anticholinergic agents are contraindicated in patients with urinary retention and 
bladder neck obstruction caused by prostatic hypertrophy since the use of these 
agents can result in an increased risk of developing an obstructive uropathy [42].
Myasthenia gravis is an autoimmune disorder of the postsynaptic neuromuscular 
junction caused by antibody-mediated blockade of neuromuscular transmission that 
results in skeletal muscle weakness. Autoimmune antibodies form at the neuromuscu-
lar junction against nicotinic acetylcholine postsynaptic receptors. Anticholinergics, 
especially agents that block nicotinic cholinergic receptors, are contraindicated 
Update in Geriatrics
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because they exacerbate muscle weakness. Further, acetylcholine esterase inhibi-
tors such as pyridostigmine are considered the mainstay of treatment. The use of 
 anticholinergic agents would antagonize the effects of these drugs [42, 43].
Stimulation of M1 and M2 receptors in the GI tract increases GI motility. 
Anticholinergics block these receptors resulting in slowed GI motility. Ogilive’s 
syndrome or colonic pseudo-obstruction, which is massive dilation of the colon 
without underlying mechanical obstruction or other organic causes, can be due 
to the use of anticholinergic agents. These drugs can lead to an adynamic colon. 
Anticholinergic drugs are contraindicated in patients with achalasia, esophageal 
stricture or stenosis, pyloroduodenal stenosing peptic ulcer disease, pyloric 
obstruction and paralytic ileus [42, 44].
Stimulation of M2 receptors in the heart slow pacemaker activity and atrioven-
tricular (AV) conduction, which decreases contractility. Blocking these receptors 
leads to sinus tachycardia and increased oxygen demand [45]. Analyses of data from 
the EPIC (European Prospective Investigation into Cancer)-Norfolk Population 
Study, which was a longitudinal, observation, community cohort study, found that 
among the 21,000 study participants there was an increase in total anticholinergic 
burden and subsequent risk of all-cause mortality and incident cardiovascular 
disease during the follow up period. ACBS scores of ≥3 were associated with a 
hazard ratio of 2.17 (p < 0.00001) for cardiovascular disease incidence and higher 
mortality. It was thought that this was a dose-dependent, class effect for the anti-
cholinergic agents. Potential mechanisms of this effect could be a pro-arrhythmic 
or pro-ischemic effect, increased hemodynamic lability, cardiac ischemia, cardiac 
dysrhythmias in the presence of ischemia, decrease heart rate variability, or an 
inflammatory response resulting in an increased risk of mortality [46]. Studies of 
the effects of inhalation antimuscarinics on cardiovascular status have been mixed 
[47]. Inhalation anticholinergic agents used in chronic obstructive pulmonary 
disease have been found to aggravate the balance of the autonomic nervous system 
leading to significantly reduced heart rate recovery following maximal cardiopul-
monary exercise [48]. In a longitudinal study of over 3700 nursing home residents 
with coronary artery disease, the use of anticholinergics was associated with an 
increased risk of hospitalization and all-cause mortality (hazard ratio 1.71 if the 
ACB score ≥ 2) [49]. Further, the use of antimuscarinics for urinary incontinence 
may also be associated with drug-dependent cardiovascular risk. Among these 
agents, darifenacin has not been associated with an increase in heart rate or QT 
prolongation because it is M3 selective and it appears to have the best cardiovascular 
safety profile. Tropsium, on the other hand, may have the highest risk of adverse 
cardiovascular events. On the basis of these drugs’ physiological effects and clinical 
trials showing increased cardiovascular risk associated with their use, it is best to 
avoid anticholinergics during the post-myocardial infarction period [50].
8.  Practical considerations for the use of anticholinergic agents in older 
agents
Anticholinergic medications are readily available over-the-counter. First gen-
eration antihistamines are available as single ingredients or in multiple symptom 
cough and cold products. Anticholinergics are marketed as over-the-counter sleep 
aids and for urinary incontinence [51–54]. A recent study examining older adults’ 
medication decision making and behavior in regards to the use of anticholinergic 
over-the-counter medications found that while seniors were concerned about 
adverse drug events, they were not aware of age-related risk associated with the use 
of anticholinergic medications [55].
9
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Anticholinergic agents are used at end-of-life (EOL) for relief of nausea in those 
with a vestibular component and more commonly, to provide symptomatic relief of 
excessive secretions. However, data is lacking to support the use of these drugs for 
this latter indication [56, 57].
Given the poor risk versus benefit of anticholinergics in older adults, there has 
been a movement to deprescribe these medications in the elderly. The DEFEAT-
polypharmacy was a deprescribing feasibility trial conducted among 46 residential 
care residents in New Zealand that targeted the use of anticholinergic and sedative 
medications in older adults. Utilizing peer-reviewed deprescribing guidelines and 
a collaborative pharmacist-led medication review approach, investigators were 
able to demonstrate a 0.34 decrease in DBI scores at 6 months. The total number of 
medications were reduced by 2.13 medications per patient. There was a statistically 
significant reduction in the number of falls in the past 90 days. There was also a 
significant improvement in frailty scores. A significant decline was also observed 
in psychiatric, neurological, autonomic and other adverse events with a decrease in 
psychiatric adverse events of 1.8 three months after deprescribing and increasing 
to 2.24 after 6 months; other potential adverse events fell by 2.8 at the end of three 
months and 4.24 at 6 months post initiation of the deprescribing intervention. 
Participants also reported lower depression scores after six months. Cognition and 
quality of life were unchanged [58].
Unfortunately, anticholinergics are sometimes prescribed as part of the pre-
scribing cascade to manage urinary incontinence associated with the use of acetyl-
cholinesterase inhibitors. A population-based retrospective cohort study of 44,884 
older adults with dementia conducted in Canada found that there was an increased 
risk (adjusted hazard ratio 1.55) of subsequently receiving an anticholinergic agent 
following the initiation of acetylcholinesterase inhibitors [59]. The Choosing Wisely 
campaign, an initiative of the American Board of Internal Medicine Foundation, 
is designed to promote conversations between clinicians and patients by help-
ing patients choose care that is supported by evidence, not duplicative of other 
tests or procedures already received, free from harm, and truly necessary. Dialog 
has started about the use of anticholinergic agents in older adults. In June 2016, 
the American Academy of Nursing made the following recommendation: “Don’t 
administer “prn” (i.e., as needed) sedative, antipsychotic or hypnotic medications 
to prevent and/or treat delirium without first assessing for, removing and treating 
the underlying causes of delirium and using nonpharmacologic delirium prevention 
and treatment approaches”. Anticholinergics are clearly identified as deliriogenic 
medications [60].
In June 2020, the American Urogynecologic Society (AUS) issued a recom-
mendation stating to “avoid using anticholinergic medication to treat overactive 
bladder in women older than 70”. This recommendation was based on the AUS’s 
concern over the ability of anticholinergic drugs to impair cognition, increase the 
risk of developing dementia and cause drowsiness and constipation, all potentially 
 detrimental adverse effects in older adults [61].
9. Conclusions
Cholinergic receptors are found throughout the body, but most especially in 
the CNS. Substances that block these receptors are available both naturally and 
pharmaceutically. Depending on the location of cholinergic receptors and their 
subtype, use of anticholinergic medications can result in adverse drug effects in 
the CNS, the eyes, the exocrine glands, the heart, the GI tract and genitourinary 
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drug events from the use of anticholinergics. Easy to use scales are available to 
assess the burden of anticholinergic agents in the drug regimen. The Beer’s List 
includes drugs that are potentially inappropriate for use in older adults because of 
their strong anticholinergic properties. Adverse events associated with the use of 
anticholinergic agents include drowsiness, sedation, cognitive impairment, confu-
sion, delirium, hallucinations, blurred vision, dizziness, falls/fractures, urinary 
retention, constipation, tachycardia and xerostomia. Anticholinergic drugs have 
also been associated with an increase in mortality. These agents are involved with 
numerous drug–drug interactions adding to the anticholinergic burden. They can 
antagonize the effects of acetylcholinesterase inhibitors, contribute to the develop-
ment of GI bleeding in patients on oral, solid forms of potassium supplementation 
and lead to hyperthermia in patients concomitantly receiving a carbonic anhydrase 
inhibitor. Anticholinergics should not be used by older adults, especially those with 
narrow angle glaucoma, obstructive uropathy, myasthenia gravis, obstructive GI 
tract disease and myocardial ischemia. Avoiding prescribing these agents whenever 
possible is the first step. If they are utilized, it is important for health care profes-
sionals to use the lowest doses possible, closely monitor for signs and symptoms of 
anticholinergic adverse events and to deprescribe as tolerated.
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